Home / Journals American Journal of Clinical and Experimental Medicine / Filamentous Fungal Infections in Immunosuppressed Patients
Filamentous Fungal Infections in Immunosuppressed Patients
Submission Deadline: May 30, 2015

This special issue currently is open for paper submission and guest editor application.

Join as Guest Editor Submit to Special Issue
Lead Guest Editor
Şahin Direkel
Department of Medical Microbiology,Faculty of Health Sciences,Giresun University, Giresun, Turkey
Guest Editor
Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to fulfill the Guest Editor application.
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=254). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
Published Papers
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.
Introduction
Fungal infections, also called mycoses, are important causes of morbidity and mortality in humans. Some fungal infections are endemic, and these infections are usually caused by fungi that are present in the environment and whose spores enter humans. Other fungal infections are said to be opportunistic because the causative agents cause mild or no disease in healthy individuals but may infect and cause severe disease in immunodeficient persons. The human airway is continuously open to the nonsterile environment where fungal spores have the potential to reach lung tissue and produce disease. In the immunocompromised host, many fungi, including species of fungi typically considered nonpathogenic, have the potential to cause serious morbidity and mortality. Over the last several decades the advent of the human immunodeficiency virus (HIV) epidemic and the increasing use of immunosuppressive drugs for serious medical conditions have dramatically increased the number of persons who are severely immunocompromised. In addition, the range and diversity of fungi that cause disease have broadened. Although Candida and Aspergillus species continue to be the fungal pathogens that most frequently cause invasive fungal disease in immunocompromised persons. For example, Aspergillus is by far the most common of these molds, and mortality rates for invasive aspergillosis exceed 90% in hematopoietic stem cell transplant recipients.

Overall, infections due to previously uncommon hyaline and dematiaceous filamentous fungi (moulds) are being reported with increasing frequency. This is significant because, despite marked advances in antifungal therapy, infections caused by opportunistic fungal infections (rare and emerging) continue to be associated with high morbidity, high mortality, and poor patient outcomes. The most prevalent filamentous fungi identified are Aspergillus spp., but Fusarium spp., Scedosporium spp., Penicillium spp., and Zygomycetes are progressively more seen Early diagnosis of invasive filamentous fungal infections and proper identification of the causative agent is crucial for guidance of therapy. This results from a combination of drug-resistant strains, lack of robust clinical studies evaluating treatments, and severe underlying diseases in the patient.

The special issue of filamentous fungal infections in immunosuppressed patients encouraged the submission of original articles of high scientific quality that investigate the pathogenesis, diagnosis, and management of diseases affecting the filamentous fungal infection region, in order to help clinicians to understand more thoroughly the etiology, diagnosis, prevention, treatment, and management of filamentous fungal infection related to underlying medical conditions. We are inviting you for submission manuscripts as research articles, case report, review articles for publish in the journal.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186